WeVote
Log In

Bill

Bill

SB 592

Preferred Drug List/Common Core Formulary; approval of a nonpreferred drug.

2025 Regular Session Introduced by Saddam Salim

SB 592 establishes procedures for Virginia health plans and Medicaid to approve nonpreferred drugs, improving patient medication access while potentially increasing healthcare costs.

Left in Education and Health
0
WeVote Research Nonpartisan
Bill Summary · SB 592

Legislative bill overview

SB 592 addresses the approval process for nonpreferred drugs under Virginia's Preferred Drug List (PDL) and Common Core Formulary. The bill establishes procedural requirements for when health plans or Medicaid must approve medications that fall outside their preferred drug lists, likely creating a mechanism for patients or providers to appeal coverage denials for non-formulary drugs.

Why is this important

This bill directly affects patient access to medications and healthcare costs. When insurance plans restrict coverage to preferred drugs, patients may face higher out-of-pocket costs or be denied access to medications their doctors believe are medically necessary. The bill's approval process could improve access to specialized or alternative treatments while also impacting insurance plan costs and pharmaceutical pricing dynamics.

Potential points of contention

  • Cost implications: Requiring approval of nonpreferred drugs could increase insurance premiums and Medicaid expenditures if patients gain broader access to more expensive medications
  • Medical necessity definitions: Disagreement over what constitutes sufficient grounds for overriding formulary restrictions and who determines medical necessity (doctors vs. insurers vs. independent reviewers)
  • Implementation burden: Health plans and Medicaid may face administrative challenges and delays in processing nonpreferred drug approval requests, potentially affecting timely patient access

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.